Home/Pipeline/SON-1010

SON-1010

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Sonnet BioTherapeutics

About Sonnet BioTherapeutics

Sonnet BioTherapeutics is a clinical-stage biotech focused on developing targeted immunotherapies using its proprietary Fully Human Albumin-Binding (FHAB™) technology platform. Its mission is to improve the safety and efficacy of cytokine therapies for cancer and peripheral neuropathies by leveraging the body's natural albumin transport system. A key strategic achievement was the December 2025 business combination with Hyperliquid Strategies Inc., creating a Nasdaq-listed entity (PURR) with a dual operational model combining biotech R&D with digital asset treasury management. The company's strategy centers on advancing its modular pipeline through internal development and strategic collaborations.

View full company profile

Therapeutic Areas

Oncology Peripheral Neuropathy

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed